Analyst Activity – Piper Jaffray Companies Reiterates Positive on CymaBay Therapeutics (NASDAQ:CBAY)

ME Staff
-
0

Analyst Ratings For CymaBay Therapeutics (NASDAQ:CBAY)

Today, Piper Jaffray Companies reiterated its Positive rating on CymaBay Therapeutics (NASDAQ:CBAY) with a price target of $12.00.

There are 5 buy ratings, 1 strong buy rating on the stock.

The current consensus rating on CymaBay Therapeutics (NASDAQ:CBAY) is Buy (Score: 3.17) with a consensus target price of $13.80 per share, a potential 73.37% upside.

Some recent analyst ratings include

  • 7/25/2017-Piper Jaffray Companies Reiterated Rating of Positive .
  • 7/20/2017-CIBC Reiterated Rating of Outperform .
  • 7/20/2017-Citigroup Inc. Reiterated Rating of Outperform.
  • 7/17/2017-Ifs Securities Reiterated Rating of Strong-Buy.
  • 7/1/2016-Roth Capital initiated coverage with a Buy rating.

Recent Insider Trading Activity For CymaBay Therapeutics (NASDAQ:CBAY)
CymaBay Therapeutics (NASDAQ:CBAY) has insider ownership of 15.10% and institutional ownership of 36.91%.

  • On 7/20/2017 Charles Mcwherter, SVP, bought 5,000 with an average share price of $7.43 per share and the total transaction amounting to $37,150.00. View SEC Filing
  • On 7/20/2017 Sujal Shah, Insider, bought 10,000 with an average share price of $7.34 per share and the total transaction amounting to $73,400.00. View SEC Filing
  • On 9/6/2016 Robert James Wills, Director, bought 25,000 with an average share price of $2.43 per share and the total transaction amounting to $60,750.00. View SEC Filing
  • On 4/15/2016 Charles Mcwherter, VP, bought 3,000 with an average share price of $1.68 per share and the total transaction amounting to $5,040.00. View SEC Filing
  • On 4/5/2016 Sujal Shah, CFO, bought 55,000 with an average share price of $1.39 per share and the total transaction amounting to $76,450.00. View SEC Filing
  • On 4/4/2016 Sujal Shah, CFO, bought 22,000 with an average share price of $1.39 per share and the total transaction amounting to $30,580.00. View SEC Filing
  • On 9/11/2015 Carl Goldfischer, Director, sold 46,729 with an average share price of $2.74 per share and the total transaction amounting to $128,037.46. View SEC Filing

Recent Trading Activity for CymaBay Therapeutics (NASDAQ:CBAY)
Shares of CymaBay Therapeutics closed the previous trading session at 7.96 up +0.03 0.38% with 1,521,789 shares trading hands.